// App-Quantinova.ai

PB1390 : Desmopressin for Reversal of Antiplatelet Drugs in Stroke due to Haemorrhage (DASH): Interim Report on Recruitment from a Phase II Double Blind Randomised Controlled Trial

Researchers

Presenter

  • M. Desborough

Principal Investigators

  • R. Al-Shahi Salman

  • S. Stanworth

  • D. Havard

  • P.M. Brennan

  • R. Dineen

  • T. Coats

  • P. Johnson

  • T. Hepburn

  • P. Bath

  • N. Sprigg

Medical Centers

  • Guy's and St Thomas' NHS Foundation Trust, Haemophilia and Thrombosis Centre, London, United Kingdom

  • University of Edinburgh, BHF/Centre for Cardiovascular Science, Edinburgh, United Kingdom

  • Oxford University Hospitals NHS Trust, Department of Cardiology, Oxford, United Kingdom

  • NHS Blood and Transplant, Clinical Research in Transfusion Medicine, Oxford, United Kingdom

  • University of Nottingham, Academic Ophthalmology- Division of ClinicalNeuroscience, Nottingham, United Kingdom

  • University of Leicester, Department of Cardiovascular Sciences, Leicester, United Kingdom

  • Patient Representative, Nottingham, United Kingdom

  • Clinical Trials Unit, University of Nottingham, Nottingham

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

Disease

  • Stroke

Biomarkers

  • N/A

Drug/Treatment

  • Desmopressin

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved